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Purpose: To report on pars plana vitrectomy (PPV) combined with pars plana lensectomy (PPL) 
with a   preserved anterior capsule, panretinal endophotocoagulation (EPC) throughout the pars 
plana, and silicon oil (SO) tamponade (PPV + PPL + EPC + SO tamponade) for neovascular 
glaucoma (NVG).
Methods: Thirteen eyes with NVG were treated. Ten eyes also underwent SO removal and 
intraocular lens (IOL) implantation (SO removal + IOL). Intraocular pressure (IOP), number of 
medications, and visual acuity were evaluated at the first visit, immediately before and 3 months 
after the procedure, 3 months after SO removal + IOL, and 1 year after the procedure.
Results: At the first visit, immediately before and 3 months after the procedure, 3 months after 
SO removal + IOL, and 1 year after the procedure, the IOPs were 29 ± 19, 23 ± 12, 13 ± 5, 
17 ± 10, and 17 ± 6 mmHg; numbers of medications, 0.7 ± 1.4, 2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, 
and 1.6 ± 1.6; and best-corrected visual acuities converted to logarithm of the minimum angle of 
resolution (BCVA logMAR), 0.96 ± 0.96, 1.27 ± 0.80, 1.67 ± 0.91, 1.37 ± 0.89, and 1.90 ± 1.44, 
respectively. No severe hypotony or phthisis bulbi developed within 1 year after the procedure. 
The success rates (IOP # 21 mmHg and sustained light perception) were 92.3% after 3 months 
and 69.2% after 1 year.
Conclusion: PPV + PPL + EPC + SO tamponade might have prevented acute increases of 
vascular endothelial growth factor and inflammatory cytokine production postoperatively and 
resulted in good vision in patients with NVG.
Keywords: pars plana vitrectomy, pars plana lensectomy, panretinal endophotocoagulation, 
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Introduction
Neovascular glaucoma (NVG) develops in cases with extensive ischemic retinal 
changes, such as proliferative diabetic retinopathy (PDR) and central retinal vein occlu-
sion (CRVO). Vascular endothelial growth factor (VEGF) and inflammatory   cytokines 
from the ischemic retina are thought to cause NVG.1–3 VEGF and inflammatory cytokines 
from the ischemic retina migrate to the anterior segment and stimulate the neovascular-
ization in the iris and the angle. When neovascular fibrous tissues occupy the trabecular 
meshwork, aqueous outflow is disturbed and NVG develops eventually.
NVG is generally difficult to treat. Prophylactic panretinal photocoagulation (PRP) 
prevents development of NVG4–6 and can be effective for early-stage NVG.7,8   Application 
of PRP induces regression of neovascularization in the angle, and aqueous outflow can be Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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initiated in open-angle NVG. However, in   angle-closure NVG, 
PRP cannot restore aqueous outflow,9–11 and trabeculectomy 
or cyclo-cryo/photocoagulation of the ciliary body is the final 
treatment option.12–14 However, the surgical results are usually 
dismal.14–17 Obtaining regression of neovascularization dur-
ing the open-angle stage of the disease is the most important 
strategy for treating NVG.
Although pars plana vitrectomy (PPV) and additional 
retinal photocoagulation are the next options for treating 
NVG, the surgical results are unfavorable. Aphakia especially 
is a risk factor for development of rubeosis.18 Patients who 
are pseudophakic are thought to have a better chance of not 
developing rubeosis postoperatively than phakic patients.19 
Considering this, we previously performed PPV + phacoemul-
sification + intraocular lens (IOL) impantation + panretinal 
endophotocoagulation (EPC) to treat NVG. However, we 
experienced some advanced cases that developed extensive 
fibrin and worsening of rubeosis despite this procedure. 
Incomplete vitrectomy and incomplete retinal photocoagu-
lation to the peripheral pars plana seem to cause extensive 
fibrin and worsening rubeosis. Therefore, we performed 
PPV combined with pars plana lensectomy (PPL) with pres-
ervation of the anterior capsule, EPC throughout the pars 
plana, and silicon oil (SO) tamponade (PPV + PPL + EPC + 
SO tamponade) to treat NVG. The aim of the current study 
was to evaluate the results of this new surgical procedure, 
PPV + PPL + EPC + SO tamponade, for open-angle NVG.
Patients and methods
Thirteen eyes of eleven cases with NVG were included 
from July 2004 to January 2007 and underwent PPV + 
PPL + EPC + SO tamponade. All eyes had undergone PRP 
previously and were diagnosed with open-angle NVG. Twelve 
eyes had a history of PDR and one eye had a history of CRVO; 
the mean patient age (mean ± standard deviation [SD]) was 
57.9 ± 10.5 years. The male:female ratio was 9:2. Ten eyes of 
nine cases also underwent SO removal and IOL implantation 
(SO removal + IOL); the mean patient age was 59.3 ± 10.6 
years. The male:female ratio was 7:2. The interval between SO 
tamponade and removal (mean ± SD) was 205 ± 91 days.
We performed PPV using a three-port technique in all 
patients. We performed PPL extraction in twelve phakic eyes 
using the Fragmatome (Alcon, Fort Worth, TX) and preserved 
the anterior lens capsule. The IOL was left in place in one 
pseudophakic eye. During PPV , posterior hyaloid separa-
tion was induced by suction using the vitreous cutter over 
the optic nerve head in a case without a posterior vitreous 
detachment. Fibrovascular membranes were removed using 
the total en-bloc excision technique.20 After PPV , EPC was 
performed throughout the pars plana, and the vitreous cavity 
was filled with SO.
We evaluated the intraocular pressure (IOP), the number 
of both antihypertensive eye drops and oral medicines used, 
and the visual acuity (VA) using a Snellen chart at the time 
of the first visit, immediately before and 3 months after 
PPV + PPL + EPC + SO tamponade, another 3 months after 
SO removal + IOL, and 1 year after PPV + PPL + EPC + SO 
tamponade. The best-corrected decimal visual acuity 
was converted to the logarithm of the minimum angle of 
resolution (BCVA logMAR). Mermoud et al21 defined 
therapeutic success as an IOP #21 mmHg and the presence 
of sustained light perception vision. Using these criteria, 
we calculated the success rates 3 months and 1 year after 
PPV + PPL + EPC + SO tamponade.
The Wilcoxon signed-rank test was used for statisti-
cal analysis in this study. The values are expressed as 
the mean ± SD. P , 0.05 was considered statistically 
significant.
Results
At the first visit, immediately before, and 3 months after 
PPV + PPL + EPC + SO tamponade, another 3 months after 
SO removal + IOL, and 1 year after PPV + PPL + EPC + SO 
tamponade, the mean IOPs (mean ± SD) were 29 ± 19, 
23 ± 12, 13 ± 5, 17 ± 10, and 17 ± 6 mmHg (Figure 1); 
the numbers of medications (mean ± SD) were 0.7 ± 1.4, 
2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, and 1.6 ± 1.6 (Figure 2); 
and the BCVA logMAR (mean ± SD) were 0.96 ± 0.96, 
1.27 ± 0.80, 1.67 ± 0.91, 1.37 ± 0.89, and 1.90 ± 1.44, 
respectively. The IOP and the numbers of both antihyperten-
sive eye drops and oral medications used for 3 months after 
PPV + PPL + EPC + SO tamponade decreased significantly 
compared with immediately before PPV + PPL + EPC + SO 
tamponade (P , 0.05). However, the IOP and the numbers 
of both antihypertensive eye drops and oral medications 
used for another 3 months after SO removal + IOL and 
1 year after PPV + PPL + EPC + SO tamponade did not 
decrease significantly compared with immediately before 
PPV + PPL + EPC + SO tamponade.
An IOP of 21 mmHg or lower was maintained in twelve 
of 13 eyes (92.3%) 3 months after PPV + PPL + EPC + SO 
tamponade, and an IOP of 21 mmHg or lower was maintained 
in eight of ten eyes (80%) 3 months after SO removal + IOL 
with or without medications. An IOP of 21 mmHg or 
lower was maintained in eleven of 13 eyes (84.6%) 1 year 
after PPV + PPL + EPC + SO tamponade with or without Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 The time course of IOP changes. At the first visit, immediately before and 3 months after PPV + PPL + ePC + sO tamponade, 3 months after sO removal + iOL, 
and 1 year after PPV + PPL + ePC + sO tamponade, the iOPs (mean ± sD) were 29 ± 19, 23 ± 12, 13 ± 5, 17 ± 10, and 17 ± 6 mmHg.
Abbreviations: mmHG, millimeters of mercury; IOP, intraocular pressure; SO, silicon oil; PPV, pars plana vitrectomy; PPL, pars plana lensectomy; EPC, endophotocoagulation; 
iOL, intraocular lens; sD, standard deviation
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Figure 2 The time course of changes in the numbers of antihypertensive eye drops and oral medications used. At the first visit, immediately before and 3 months after 
PPV + PPL + ePC + sO tamponade, 3 months after sO removal + IOL, and 1 year after PPV + PPL + ePC + sO tamponade, the numbers of medications used (mean ± sD) 
were 0.7 ± 1.4, 2.1 ± 2.0, 0.6 ± 0.7, 1.2 ± 1.2, and 1.6 ± 1.6.
Abbreviations: sO, silicon oil; PPV, pars plana vitrectomy; PPL, pars plana lensectomy; EPC, endophotocoagulation; IOL, intraocular lens; SD, standard deviation
medications. No eyes developed severe hypotony or 
phthisis bulbi within 1 year after PPV + PPL + EPC + SO 
tamponade. Twelve of 13 eyes (92.3%) had light per-
ception vision 3 months after PPV + PPL + EPC + SO 
  tamponade. Six of ten eyes (60%) had improved VA 3 months 
after SO removal + IOL compared with 3 months after 
PPV + PPL + EPC + SO tamponade but this improvement 
was not statistically significant. Ten of 13 eyes (76.9%) had 
light perception vision 1 year after PPV + PPL + EPC + SO 
tamponade. The success rates of our procedure were 92.3% 
after 3 months and 69.2% after 1 year.
Discussion
The surgical results were considered successful because the 
IOP was well controlled with or without medications and the 
visual prognosis was good compared with previous reports of 
vitreous surgery for NVG.22–25 In our surgical technique, exten-
sive PRP throughout the pars plana can be applied thanks to 
PPV + PPL.  The major difference between our technique and 
previously reported vitreous surgery for NVG is that migration 
of VEGF and inflammatory cytokines from the posterior to the 
anterior segment is blocked as a result of preservation of the 
anterior lens capsule and SO tamponade. Rice et al26 reported 
a significant increase in the postoperative incidence of NVG 
in eyes undergoing combined lensectomy and vitrectomy com-
pared with eyes in which the lens was not removed. Vitreous 
surgery without preservation of the anterior lens capsule and 
SO may induce acute production of VEGF and inflammatory 
cytokines because of retinal damage caused by PRP, which 
results in an acute immediate worsening of the NVG.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Bartz-Schmidt et al22 reported on the results of lensectomy 
including removal of the lens capsule + PPV + EPC + SO 
tamponade to treat NVG. The differences compared with 
the current procedure were application of PRP to the ciliary 
body and the lens capsule was not preserved. Those authors 
applied PRP to the ciliary body to decrease the aqueous 
humor yield, but the incidence rate of severe hypotony or 
phthisis bulbi was high.22 We did not observe hypotony 
and phthisis bulbi in the current cases, because we did not 
apply EPC to the ciliary body. The current procedure differs 
from that of Bartz-Schmidt et al22 in that the ciliary body 
was intact, because the aim of the current procedure was 
to prevent migration of VEGF and inflammatory cytokines 
from the posterior to the anterior segment. Therefore, the 
current procedure might not be as effective for treating 
advanced angle-closure NVG, although this procedure 
might be considered to achieve regression of rubeosis. In 
cases of angle-closure NVG, trabeculectomy or cyclo-cryo/
photocoagulation of the ciliary body should be performed 
after our procedure.
Trabeculectomy combined with injection of an anti-
VEGF agent into the vitreous body was performed recently. 
However, the long-term effect of decreasing the IOP was 
insubstantial compared with trabeculectomy alone.27,28 The 
anti-VEGF agents caused temporary regression of the iris 
neovascularization, but the effect dissipated over time.
In conclusion, although NVG remains hard to treat, there 
may be a chance to preserve the visual function. It is impor-
tant to prevent the transition from open-angle to angle-closure 
NVG by performing the procedure at the earliest possible 
opportunity. PPV + PPL + EPC + SO tamponade prevented 
blindness in our case series. We strongly recommend this 
procedure to treat NVG because it might effectively block 
VEGF and inflammatory cytokine production with preserva-
tion of the anterior lens capsule and SO.
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